
AVXL
Healthcare · Biotechnology · $86.5M market cap
$0.9335-0.06 (-5.6%)Nov 13, 4:00 PM EST
Next report
Before the open
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -4.8% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 24, 2026 · upcoming | Before the open | -0.11 | — | — |
| Aug 25, 2026 | Before the open | -0.08 | 0.08 | +200.0% |
| Jun 30, 2026 | Time not confirmed | -0.07 | -0.13 | -85.7% |
| Feb 9, 2026 | Before the open | -0.11 | -0.06 | +45.5% |
| Nov 25, 2025 | Time not confirmed | -0.14 | -0.11 | +22.9% |
| Aug 12, 2025 | Before the open | -0.14 | -0.16 | -14.3% |
| May 13, 2025 | Before the open | -0.15 | -0.13 | +13.3% |
| Feb 12, 2025 | Before the open | -0.17 | -0.14 | +17.6% |
| Nov 25, 2024 | Before the open | -0.17 | -0.14 | +17.6% |
| Aug 6, 2024 | Before the open | -0.18 | -0.14 | +22.2% |
| May 9, 2024 | Before the open | -0.13 | -0.13 | 0.0% |
| Feb 7, 2024 | Before the open | -0.15 | -0.11 | +26.7% |
| Nov 27, 2023 | Before the open | -0.15 |
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a…
| -0.12 |
| +20.0% |
| Aug 8, 2023 | Before the open | -0.17 | -0.14 | +17.6% |
| May 9, 2023 | After the close | -0.18 | -0.17 | +5.6% |
| Feb 7, 2023 | Before the open | -0.19 | -0.17 | +10.5% |
| Nov 28, 2022 | Before the open | -0.16 | -0.18 | -12.5% |
| Aug 9, 2022 | Before the open | -0.16 | -0.16 | 0.0% |
| May 10, 2022 | Before the open | -0.17 | -0.14 | +17.6% |
| Feb 9, 2022 | Before the open | -0.16 | -0.14 | +12.5% |
| Nov 24, 2021 | Before the open | -0.14 | -0.15 | -7.1% |
| Aug 12, 2021 | Before the open | -0.14 | -0.14 | 0.0% |
| May 13, 2021 | Before the open | -0.15 | -0.12 | +20.0% |
| Feb 11, 2021 | Before the open | -0.12 | -0.12 | 0.0% |
| Dec 28, 2020 | Before the open | -0.13 | -0.10 | +23.1% |
| Aug 6, 2020 | Before the open | -0.13 | -0.11 | +15.4% |
| May 7, 2020 | Before the open | -0.16 | -0.12 | +25.0% |
| Feb 6, 2020 | Before the open | -0.12 | -0.12 | 0.0% |
| Dec 16, 2019 | Before the open | -0.15 | -0.07 | +53.3% |
| Aug 7, 2019 | Before the open | -0.17 | -0.14 | +17.6% |
| May 8, 2019 | Before the open | -0.14 | -0.17 | -21.4% |
| Feb 7, 2019 | Before the open | -0.13 | -0.16 | -23.1% |
| Dec 12, 2018 | Before the open | -0.11 | -0.13 | -18.2% |
| Aug 9, 2018 | Before the open | -0.10 | -0.06 | +40.0% |
| May 10, 2018 | Before the open | -0.10 | -0.11 | -10.0% |
| Feb 7, 2018 | Before the open | -0.08 | -0.09 | -12.5% |